

AMENDMENT NO. 1 TO CLINICAL TRIAL AGREEMENT

Between

CardioPharm International, Inc. ("Sponsor")

and

Memorial Medical Center ("Institution")

Original Agreement Date: January 15, 2022

Amendment No. 1 Effective Date: June 22, 2022

RECITALS

WHEREAS, Sponsor and Institution entered into a Clinical Trial Agreement dated January 15, 2022 (the "Agreement") for the conduct of Study Protocol No. CP-2847-301 (HEARTBEAT-3);

WHEREAS, Sponsor has issued Protocol Amendment No. 1 dated May 30, 2022, which adds a cardiac MRI at Visit 7 (Week 24) and extends follow-up from 52 weeks to 64 weeks;

WHEREAS, the parties desire to amend the Agreement to reflect the Protocol Amendment and associated budget adjustments;

NOW, THEREFORE, in consideration of the mutual covenants herein, the parties agree as follows:

AMENDMENTS

1. Protocol Update

Section 2.1 of the Agreement is hereby amended to reference Protocol No. CP-2847-301, Version 2.0 dated May 30, 2022 (Protocol Amendment No. 1), which is attached hereto as Exhibit A-1 and incorporated by reference.

2. Study Timeline Extension

Section 2.3 of the Agreement is hereby amended to read as follows:

"2.3 Study Timeline. The Study is anticipated to be completed within twenty-two (22) months from Site Activation, including a twelve (12) month enrollment period and ten (10) month follow-up period."

3. Budget Revision

Exhibit B (Budget and Payment Schedule) of the Agreement is hereby deleted in its entirety and replaced with the revised Exhibit B-1 attached hereto as Attachment 1 to this Amendment No. 1.

The revised budget reflects the following changes:

- Addition of cardiac MRI at Week 24 (+\$800 per patient)
- Addition of two follow-up visits at Week 56 and Week 64 (+\$800 per patient each)
- Increase in per-patient total from \$18,500 to \$21,200

4. Site Budget Total

The total estimated site budget increases from approximately \$408,100 to approximately \$462,100 based on 20 enrolled patients.

GENERAL PROVISIONS

5. Ratification

Except as specifically modified by this Amendment No. 1, all terms, conditions, and provisions of the Agreement dated January 15, 2022, shall remain in full force and effect and are hereby ratified and

confirmed.

6. Counterparts

This Amendment may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

7. Governing Law

This Amendment shall be governed by the laws of the State of Ohio, consistent with the Agreement.

SIGNATURES

CARDIOPHAM INTERNATIONAL, INC.

By: _____

Name: Michael Rodriguez

Title: VP, Clinical Operations

Date: June 22, 2022

MEMORIAL MEDICAL CENTER

By: _____

Name: Dr. Patricia Williams

Title: Director, Clinical Research Office

Date: June 22, 2022

ATTACHMENT 1 TO AMENDMENT NO. 1: REVISED EXHIBIT B-1

BUDGET AND PAYMENT SCHEDULE (REVISED)

Study: HEARTBEAT-3 (Protocol CP-2847-301, Version 2.0)

Site: Memorial Medical Center

PI: Dr. Sarah Chen

Enrollment Target: 20 patients

Budget Version: 1.1

Date: June 22, 2022

SITE STARTUP COSTS (No Change)

Item	Amount
IRB Submission & Approval	\$3,500
Regulatory Document Preparation	\$2,000
Site Initiation Visit	\$4,000
Site Activation Payment	\$5,000
TOTAL STARTUP	\$14,500

PER-PATIENT COSTS (REVISED)

Target Enrollment: 20 patients

Per-Patient Total: \$21,200 (increased from \$18,500)

Visit	Procedures	Payment per Patient
Screening	Consent, vitals, ECG, echo, labs, medical history	\$2,200
Baseline/Randomization	Vitals, ECG, labs, drug dispensing	\$1,100
Week 4	Vitals, ECG, labs, drug dispensing	\$900
Week 8	Vitals, ECG, labs, drug dispensing	\$900
Week 12	Vitals, ECG, echo, labs, drug dispensing	\$1,600
Week 16	Vitals, ECG, labs, drug dispensing	\$900
Week 20	Vitals, ECG, labs, drug dispensing	\$900
Week 24	Vitals, ECG, echo, cardiac MRI , labs, drug dispensing	\$2,400 (+\$800)
Week 28	Vitals, ECG, labs, drug dispensing	\$900
Week 32	Vitals, ECG, labs, drug dispensing	\$900
Week 36	Vitals, ECG, echo, labs, drug dispensing	\$1,600
Week 40	Vitals, ECG, labs, drug dispensing	\$900
Week 44	Vitals, ECG, labs, drug dispensing	\$900
Week 48 (End of Treatment)	Vitals, ECG, echo, labs, safety follow-up	\$1,600
Week 52 (Follow-up)	Vitals, ECG, labs, safety follow-up	\$800
Week 56 (Follow-up) - NEW	Vitals, ECG, labs, safety follow-up	\$800

Visit	Procedures	Payment per Patient
Week 64 (Final Follow-up) - NEW	Vitals, ECG, echo, labs, final safety assessment	\$1,600
TOTAL PER PATIENT		\$21,200

Total for 20 Patients: \$424,000 (increased from \$370,000)

SCREEN FAILURE PAYMENT (No Change)

Per Screen Failure: \$1,200

Estimated Screen Failures (30% rate): 8 patients

Estimated Screen Failure Total: \$9,600

SITE CLOSEOUT (No Change)

Item	Amount
Close-Out Visit	\$3,000
Final Query Resolution	\$1,500
Drug Accountability & Return	\$500
Document Archival	\$1,000
TOTAL CLOSEOUT	\$6,000

PASS-THROUGH COSTS (Revised)

Institution may invoice for the following at actual cost with documentation:

- Central laboratory costs (pre-approved vendor)
- ECG reading fees (central ECG lab)
- Echocardiogram reading fees (core lab)
- **Cardiac MRI reading fees (core imaging lab) - NEW**
- Unscheduled visits required for safety monitoring

Estimated Pass-Through Costs: \$12,000 (increased from \$8,000 due to MRI core lab fees)

TOTAL SITE BUDGET (REVISED)

Category	Amount
Site Startup	\$14,500
Per-Patient Costs (20 patients)	\$424,000
Screen Failures (estimated 8)	\$9,600
Site Closeout	\$6,000
Pass-Through Costs (estimated)	\$12,000
TOTAL BUDGET	\$466,100

PAYMENT TERMS (No Change)

- **Holdback:** 10% of per-patient payments retained until LPLV + query resolution + closeout
- **Payment Schedule:** Net 30 from invoice receipt
- **Invoicing:** Monthly invoicing permitted for completed visits
- **Holdback Release:** Within 60 days of closeout completion

